AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • February 23rd, 2017 • INSMED Inc • Pharmaceutical preparations
Contract Type FiledFebruary 23rd, 2017 Company IndustryThis Amendment to EMPLOYMENT AGREEMENT (this "Amendment"), is made and entered into as of September 26, 2016 (the "Effective Date") by and between Insmed Incorporated, a Virginia corporation (the "Company"), and S. Nicole Schaeffer (the "Executive") (each of the Executive and the Company, a "Party", and collectively, the "Parties").
November 30, 2016 VIA E-MAIL Martha J. Demski Chief Financial Officer Ajinomoto Althea, Inc. 11040 Roselle Street San Diego, CA 92121 RE: Extension of Commercial Fill/Finish Services Agreement Dear Ms. Demski,INSMED Inc • February 23rd, 2017 • Pharmaceutical preparations
Company FiledFebruary 23rd, 2017 IndustryAs you know, Ajinomoto Althea, Inc. ("Althea") and Insmed Incorporated ("Insmed") are parties to the Commercial Fill/Finish Supply Agreement, dated January 1, 2015 (the "Agreement"). Per Section 7.1 of the Agreement, the Initial Term (as defined in the Agreement) of the Agreement expires December 31, 2017 and the parties may mutually agree to extend the Agreement for an additional two (2) year period at least one (1) year prior to the expiration. Insmed kindly requests that Althea acknowledge and agree to a two (2) year extension of the Agreement until December 31, 2019 by signing below.
CONFIDENTIAL TREATMENT HAS BEEN REQUESTED AS TO CERTAIN PORTIONS OF THIS DOCUMENT. EACH SUCH PORTION, WHICH HAS BEEN OMITTED HEREIN AND REPLACED WITH ASTERISKS (***), HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE...License Agreement • February 23rd, 2017 • INSMED Inc • Pharmaceutical preparations • New York
Contract Type FiledFebruary 23rd, 2017 Company Industry JurisdictionThis License Agreement (the “Agreement”) is made and entered into effective as of October 4, 2016 (the “Effective Date”), by and between AstraZeneca AB, a company incorporated in Sweden under no. 556011-7482 with its registered office at SE-151 85 Södertälje, Sweden and with offices at SE-431 83 Mölndal, Sweden (“AstraZeneca”) and Insmed Incorporated, a Virginia corporation with offices at 10 Finderne Ave., Building 10, Bridgewater, NJ 08807-3365 U.S.A. (“Insmed”). AstraZeneca and Insmed are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”